On October 22, 2024, Shanghai UnionClin Co., Ltd. (hereinafter referred to as UnionClin) was conducting "A Phase 1b/2a Clinical Study of JJH201601 Liposome Injection for the Treatment of Patients with Advanced Pancreatic Cancer, Biliary Tract Cancer, and Hepatocellular Carcinoma" at Nanjing Tianyinshan Hospital, and the first subject was successfully enrolled and treated.

Clinical Research Associates (CRAs) and Clinical Research Coordinators (CRCs) are important forces assisting sponsors and investigators in conducting clinical studies and are frontline workers responsible for controlling and ensuring the quality of clinical studies. 

On March 15, 2024, UnionClin invited insightful and influential experts and leaders in the field of pharmaceutical innovation, together with pharmaceutical colleagues from various sectors, to gather in Gusu, and the UnionClin Suzhou Salon concluded successfully.

On October 23, in collaboration with Union Laiya and East Hospital, successfully held an academic salon on industry-university-research cooperation for innovative drugs. They had the honor of inviting the original inventor of the BOIN design (the first innovative Phase I clinical study design invented by a Chinese professor and certified by the U.S. FDA)

On October 27, UnionClin, in collaboration with Hangzhou Biopharma Town, Hongren Pharmaceutical, and Hangzhou HDXX, invited clinical medical experts, experienced audit mentors, outstanding industry enterprises, and professional partners to gather in Hangzhou. Focusing on the challenges throughout the entire process from new drug development to market launch, they engaged in brainstorming through practical case studies, bringing brilliant and insightful interpretations.

On June 18, 2023, hosted by UnionClin and co-organized with Genhouse and Taizhou Enze Medical Center, the thematic salon titled "Challenges and Responses Faced in Early Clinical Studies of New Oncology Drugs" was successfully held at Taizhou Hospital.